论文部分内容阅读
由中国科学院生物物理研究所和江苏省海安生化药物研究所共同开发研制的“抗癌长生灵”临床前科研鉴定会,三月在山西省稷山县太阳村召开。“抗癌长生灵”制剂由河蚌中提得,经制剂工艺,质量控制及动物抗癌药理实验、毒性实验等项研究,现巳基本完成临床前科研要求。鉴定会上,来自北京、黑龙江、陕西、山东、山西等地的专家、教授听取了科研
The preclinical research and appraisal meeting of “Anticancer Changshengling” jointly developed by the Institute of Biophysics of the Chinese Academy of Sciences and the Jiangsu Haian Biochemical Pharmaceutical Research Institute was held in Sun Village, Dangshan County, Shanxi Province in March. “Anticancer Changshengling” preparations were obtained from Hexi Zhongtuo, followed by research on preparation technology, quality control, and animal anticancer pharmacology experiments, toxicity experiments, etc. Now the preclinical research requirements are basically completed. At the appraisal meeting, experts and professors from Beijing, Heilongjiang, Shaanxi, Shandong, and Shanxi Province heard scientific research